RAF-265

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRAF-265
Drug Alias NameRAF-265CHIR-265
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsSerine/threonine-protein kinase B-raf inhibitorsC-Raf kinase inhibitors +[4] 
TargetsVascular endothelial growth factor receptor 2Serine/threonine-protein kinase B-rafC-Raf kinase +[4] 
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgChiron Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A